Renaissance Capital logo

CINC News

Recent listings are now prime acquisition targets

CinCor Pharma logo

Recent IPOs saw their valuations collapse in 2022, but as public investors sit on the sidelines, buyout firms and corporations are hunting for bargains amid the IPO wreckage. For companies that have gone public via IPO or SPAC merger since 2015, more than 40...read more

Updated: Renaissance Capital's 2022 US IPO Market Review

CinCor Pharma logo

The IPO Market Flips from Boom to Bust in 2022 After the prior year’s record activity, the 2022 US IPO market ground to a halt as the war in Ukraine, a valuation correction in high-multiple...read more

Nearly 90% of 2022's large IPOs are trading above issue

CinCor Pharma logo

While market conditions are still keeping the IPO window mostly closed, the year's large issuers are finding support, especially over the past few months. Excluding high-flying outlier HKD, just 15 IPOs have raised $100 million or more in 2022, and 13 (87%)...read more

2022's energy and healthcare IPOs currently average solid returns amid challenging conditions

CinCor Pharma logo

IPO activity is still muted heading into the final stretch of 2022, weighed down by poor trading from new issuers. Despite challenging current market conditions, the energy and healthcare sectors have delivered solid trading recently, and are the only two...read more